Ra reports mixed data from Phase II trial of PNH candidate

Ra Pharmaceuticals Inc. (NASDAQ:RARX) reported data from a Phase II trial to treat paroxysmal nocturnal hemoglobinuria (PNH) showing that subcutaneous RA101495

Read the full 217 word article

User Sign In